Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Integrated BiopharmaINBP +5.56%36 3-1 Month Momentum % is -17.72% as of Aug. 31, 2026. GuruFocus rates INBP with a GF Score™ of 36/100 and a GF Value™ of $0.26 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 2,038 Consumer Packaged Goods companies, Integrated Biopharma ranks worse than 86.41% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-31), Integrated Biopharma's 3-1 Month Momentum % is -17.72%.
The industry rank for Integrated Biopharma's 3-1 Month Momentum % or its related term are showing as below:
INBP's 3-1 Month Momentum % is ranked worse than 86.41% of 2038
companies
in the Consumer Packaged Goods industry
Industry Median: -2.09
vs INBP: -17.72
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Integrated Biopharma 3-1 Month Momentum % Related Terms
INBP vs CIMG, BABB, PAVS: 3-1 Month Momentum % Comparison
For the Packaged Foods subindustry, Integrated Biopharma's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Integrated Biopharma 3-1 Month Momentum % vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Integrated Biopharma's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Integrated Biopharma's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Integrated Biopharma (INBP) has a 3-1 Month Momentum % of -17.72% as of Aug. 31, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Integrated Biopharma and its competitors. According to the industry distribution chart, Integrated Biopharma ranks #1761 out of 2038 companies in the Consumer Packaged Goods industry, placing it in the top 86.4%.
Is Integrated Biopharma's 3-1 Month Momentum % too high?
Integrated Biopharma's current 3-1 Month Momentum % is -17.72%. Based on the distribution chart, Integrated Biopharma ranks #1761 out of 2038 companies in the Consumer Packaged Goods industry, which is in the bottom quartile relative to peers. Overall, Integrated Biopharma has a GF Score™ of 36/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Integrated Biopharma's 3-1 Month Momentum % compare to CIMG and BABB?
According to the Consumer Packaged Goods industry distribution chart, Integrated Biopharma ranks #1761 out of 2038 companies for 3-1 Month Momentum %. This places Integrated Biopharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Consumer Packaged Goods company?
A good 3-1 Month Momentum % depends on the Consumer Packaged Goods industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Integrated Biopharma and its competitors. Integrated Biopharma's current 3-1 Month Momentum % is -17.72%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Integrated Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Integrated Biopharma (INBP) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.26, compared to a current price of $0.19 — trading 26.9% below its estimated fair value. The current 3-1 Month Momentum % is -17.72%. Integrated Biopharma's overall GF Score™ is 36/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Integrated Biopharma (INBP), the current 3-1 Month Momentum % is -17.72% as of Aug. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Integrated Biopharma (INBP) Overvalued in 2026?
Based on GuruFocus' analysis, Integrated Biopharma stock appears to be undervalued.
The current stock price of $0.19 is trading 26.9% below its estimated GF Value™ of $0.26.
GuruFocus considers Integrated Biopharma to be Modestly Undervalued.
Key valuation signals for INBP:
3-1 Month Momentum %: -17.72%
GF Value™: $0.26 vs. price of $0.19 (26.9% below fair value)
No single metric tells the full story. See the INBP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Integrated Biopharma Inc is a pharmaceutical company engaged in manufacturing, distributing, marketing, and selling vitamins, nutritional supplements, and herbal products. It operates in two segments: Contract Manufacturing and Other Nutraceutical Businesses. Key revenue is generated from the Contract Manufacturing segment, which manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers, and specialized health-care providers.
36GF Score
Get the complete analysis for INBP
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INBP has been successfully added to your 
